Bloomberg Billionaires Index

View profiles for each of the world’s 500 richest people, see the biggest movers, and compare fortunes or track returns.

# 396 Seo Jung-Jin $6.07B

Random fact: Made sudden announcement to sell Celltrion; later retracted.


Seo is the founder and chairman of Celltrion, a South Korean manufacturer of generic medical products made from living cells. The Incheon-based company is publicly traded and had revenue of 1,849.1 billion won ($1.6 billion) in 2020. One of Celltrion's most successful drugs is Remsima, a treatment for rheumatoid arthritis.

As of :
Last change +$131M ( +2.2%)
YTD change -$688M ( -10.2%)
Biggest asset 068270 KS Equity
Country / Region Korea, Republic of
Age 64
Industry Health Care
View net worth over:   Max 1 year 1 quarter 1 month 1 week

Relative Value

Seo Jung-Jin's net worth of $6.07B can buy ...

troy ounces of gold
barrels of crude oil

... and is equivalent to ...

of the GDP of the United States
of the total wealth of the 500 richest people in the world
of the top 100 U.S. college endowments
of the top 200 U.S. executives’ total awarded compensation
of U.S. existing home sales
times the median U.S. household income

Latest News

Net Worth Summary

Private asset
Public asset
Misc. liabilities
Confidence rating:

The majority of Seo's fortune is derived from Celltrion, a publicly traded manufacturer and distributor of biological pharmaceuticals based in Incheon, South Korea. The company reported revenue of 1,849.1 billion won ($1.6 billion) in 2020, according to its website.

Seo owns 20% stake of the business through two holding companies, Celltrion Holdings and Celltrion Skincure, in which he controls 93.9% and 69.7% stakes, respectively, according to Celltrion's 2021 third-quarter report. Pledged shares held through the two holding companies are removed from the net worth calculation.

He also has a 36% stake in Celltrion Healthcare, which markets, sells and distributes drugs made by Celltrion, directly and through Celltrion Skincure, according to the company's 2021 semi-annual report. Pledged shares are removed.

A liability is included to reflect an analysis of dividends, insider transactions, taxes and market performance.

Lee Gunn, a spokesman at Celltrion, declined to comment on the billionaire's net worth.


Birthdate: 10/23/1957
Family: Married, 2 children
Education: Konkuk University, Konkuk University

Seo was born in Chungju in South Korea's North Chungchung Province in 1957 and graduated with a degree in industrial engineering from Konkuk University in Seoul in 1983.

Seo worked at two South Korean chaebols, Samsung and Daewoo, before starting his own business. He lost his job as a strategic adviser at Daewoo Motor in 1999 during the Asian financial crisis.

After leaving Daewoo, Seo flew to San Francisco seeking inspiration for a new business. During his stay at a $70-a-night hotel, he chanced upon a discussion on biosimilars, a term used to describe generic copies of biological drugs, according to the Financial Times. He subsequently decided to enter the industry.

Seo set up Celltrion in 2002 in a joint venture with San Francisco-based Vax Gen. Other initial investors included Nexol Corp., Korean Tobacco and Ginseng. Its first manufacturing plant was completed in 2005. The closely held business became a listed one the following year when it took over publicly-traded ORChem.

Celltrion had a breakthrough in July 2013, when its rheumatoid arthritis treatment, Remsima, a copycat of Merck's Remicade, got approval from the European Medicines Agency.

Seo stepped down as chief executive of Celltrion in 2013 and remains the company's chairman.

  • 1986 Employed at Korean Productivity center as a consultant.
  • 2002 Seo founds Celltrion.
  • 2008 Celltrion goes public on the Kosdaq market.
  • 2010 Draws investment from Singapore state fund Temasek Holdings.
  • 2013 Celltrion's biosimilar drug Remsima gets approved by the EMA.
  • 2013 European sales of Remsima commence.
  • 2017 Celltrion Healthcare goes public with an IPO.
  • 2017 Celltrion decides moving to the main bourse Kospi from the Kosdaq.